Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Strategy Inc. (MSTR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Strategy Inc.Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Strategy Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Strategy Inc. trades at $97.61 (market cap $37.84B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.

MSTRXBI
Market Cap
$37.84B
Sector
TechnologyBroad Market / Factor
52-Week High
$394.39$164.28
52-Week Low
$82.31$86.92
Enterprise Value
$56.61B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Strategy Inc.

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.

Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI